Cost analysis of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and the risk factors for their increased cost in a public insurance health care system - Single centre study.

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F20%3A73605938" target="_blank" >RIV/61989592:15110/20:73605938 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00098892:_____/20:N0000126

Výsledek na webu

<a href="https://reader.elsevier.com/reader/sd/pii/S0748798320300214?token=4E1EAAD45AB2B94F8E348E43EC8BEAAD773029628FA68B6986DF02BA92B51BCD4C9BC9ECCB24A583C9A2FB40000AEB74" target="_blank" >https://reader.elsevier.com/reader/sd/pii/S0748798320300214?token=4E1EAAD45AB2B94F8E348E43EC8BEAAD773029628FA68B6986DF02BA92B51BCD4C9BC9ECCB24A583C9A2FB40000AEB74</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ejso.2020.01.020" target="_blank" >10.1016/j.ejso.2020.01.020</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Cost analysis of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and the risk factors for their increased cost in a public insurance health care system - Single centre study.

Popis výsledku v původním jazyce

Introduction: This study aimed to evaluate the costs of CRS and HIPEC and treatment of the related postoperative complications in the public healthcare system. We also aimed to identify the risk factors that increase the cost of CRS and HIPEC. Materials and methods: We retrospectively evaluated 80 patients who underwent CRS and HIPEC between February 2016 and November 2018 in the Department of Surgery, University Hospital of Olomouc, Czech Republic. Intraoperative factors and postoperative complications were assessed. The treatment cost included the surgery, hospital stay, intensive care unit (ICU) admission, pharmaceutical charges including medication, hospital supplies, pathology, imaging, and allied healthcare services. Results: The postoperative morbidity rate was 50%, and the mortality rate was 2.5%. The mean length of hospitalisation and ICU admission was 15.44 ± 8.43 and 6.15 ± 4.12 for all 80 patients and 10.73 ± 2.93 and 3.73 ± 1.32, respectively, for 40 patients without complications, and 20.15 ± 13.93 and 8.58 ± 6.92, respectively, for 40 patients with complications. The total treatment cost reached V606,358, but the total reimbursement was V262,931; thus, the CRS and HIPEC profit margin was V-343,427. Multivariate analysis showed that blood loss 1.000 ml (p ¼ 0.03) and grade IeV Clavien-Dindo complications (p &lt; 0.001) were independently associated with increased costs. Conclusion: The Czech public health insurance system does not fully compensate for the costs of CRS and HIPEC. Hospital losses remain the main limiting factor for further improving these procedures. Furthermore, treatment costs increase with increasing severity of postoperative complications.

Název v anglickém jazyce

Cost analysis of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and the risk factors for their increased cost in a public insurance health care system - Single centre study.

Popis výsledku anglicky

Introduction: This study aimed to evaluate the costs of CRS and HIPEC and treatment of the related postoperative complications in the public healthcare system. We also aimed to identify the risk factors that increase the cost of CRS and HIPEC. Materials and methods: We retrospectively evaluated 80 patients who underwent CRS and HIPEC between February 2016 and November 2018 in the Department of Surgery, University Hospital of Olomouc, Czech Republic. Intraoperative factors and postoperative complications were assessed. The treatment cost included the surgery, hospital stay, intensive care unit (ICU) admission, pharmaceutical charges including medication, hospital supplies, pathology, imaging, and allied healthcare services. Results: The postoperative morbidity rate was 50%, and the mortality rate was 2.5%. The mean length of hospitalisation and ICU admission was 15.44 ± 8.43 and 6.15 ± 4.12 for all 80 patients and 10.73 ± 2.93 and 3.73 ± 1.32, respectively, for 40 patients without complications, and 20.15 ± 13.93 and 8.58 ± 6.92, respectively, for 40 patients with complications. The total treatment cost reached V606,358, but the total reimbursement was V262,931; thus, the CRS and HIPEC profit margin was V-343,427. Multivariate analysis showed that blood loss 1.000 ml (p ¼ 0.03) and grade IeV Clavien-Dindo complications (p &lt; 0.001) were independently associated with increased costs. Conclusion: The Czech public health insurance system does not fully compensate for the costs of CRS and HIPEC. Hospital losses remain the main limiting factor for further improving these procedures. Furthermore, treatment costs increase with increasing severity of postoperative complications.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

EJSO

ISSN

0748-7983

e-ISSN

—

Svazek periodika

46

Číslo periodika v rámci svazku

4 Part A

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

6

Strana od-do

607-612

Kód UT WoS článku

000527364200018

EID výsledku v databázi Scopus

2-s2.0-85078096848